MBX Biosciences, Inc. Common Stock (MBX) Earnings Yield: History & Chart

MBX Biosciences, Inc. Common Stock(MBX)

Biotechnology · Carmel, IN

$56.00-2.54 (-4.34%)

Delayed quote: Oct 6, 2026, 1:05 PM EDT

About MBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

Carmel, IN

63 employees

mbxbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Steve Hoerter

View full financials

NAME	MARKET CAP	EARNINGS YIELD	TTM	3Y	5Y
MBX Biosciences, Inc. Common Stock (MBX)	$2.67B	N/A	N/A	N/A	N/A
Acadia Healthcare Company, Inc. (ACHC)vs ›	$2.67B	N/A	8.33%	6.72%	5.70%
Aveanna Healthcare Holdings Inc. (AVAH)vs ›	$2.67B	10.30%	9.07%	6.61%	6.61%
Neogen Corporation (NEOG)vs ›	$2.66B	N/A	0.18%	1.09%	1.28%
Precigen, Inc. (PGEN)vs ›	$2.71B	N/A	7.93%	7.93%	7.93%
Privia Health Group, Inc. (PRVA)vs ›	$2.58B	1.06%	0.72%	0.76%	0.75%
Beam Therapeutics Inc. (BEAM)vs ›	$2.58B	N/A	N/A	N/A	N/A
NewAmsterdam Pharma Company N.V. (NAMS)vs ›	$2.57B	N/A	1.58%	1.58%	1.58%
AtriCure, Inc. (ATRC)vs ›	$2.79B	0.39%	0.43%	0.43%	1.84%
TransMedics Group, Inc. (TMDX)vs ›	$2.81B	4.75%	3.82%	2.33%	2.33%

NAME

MARKET CAP

EARNINGS YIELD

TTM

MBX Biosciences, Inc. Common Stock (MBX)

$2.67B

N/A

Acadia Healthcare Company, Inc. (ACHC)vs ›

$2.67B

N/A

8.33%

6.72%